Loading…
LUMEFANTRINE DISPOSITION AFTER REPETITIVE TREATMENT OF UNCOMPLICATED MALARIA PATIENTS WITH ARTEMETHER-LUMEFANTRINE IN MALI
BackgroundSince 2006 the national malaria control program in Mali recommended artemether-lumefantrine (AL) as the first-line treatment of uncomplicated malaria. The role of lumefantrine in this combination is to eliminate remaining parasites after the action of artemether and to protect the patient...
Saved in:
Published in: | BMJ global health 2017-02, Vol.2 (Suppl 2), p.A24-A24 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | A24 |
container_issue | Suppl 2 |
container_start_page | A24 |
container_title | BMJ global health |
container_volume | 2 |
creator | Tekete, Mamadou Burhenne, Juergen Fofana, Bakary Toure, Sekou Dama, Souleymane Dara, Nianwalou Traore, Oumar Sidibe, Bouran Djimde, Abdoulaye Haefeli, Walter Borrmann, Steffen |
description | BackgroundSince 2006 the national malaria control program in Mali recommended artemether-lumefantrine (AL) as the first-line treatment of uncomplicated malaria. The role of lumefantrine in this combination is to eliminate remaining parasites after the action of artemether and to protect the patient against a new blood infection. Some studies showed a correlation between lumefantrine's day 7 concentration and the efficacy of AL after treatment of a single episode of malaria. The objective of this work is to validate this observation after repetitive treatment of uncomplicated malaria patients with AL.MethodsDuring a phase IIIb/IV comparative, randomised, multicentre, clinical study of artemisinin-based combination therapies, we collected plasma on Day 7 from patients treated with standard dose of AL in Sotuba, Bougoula Hameau, and Kolle (Mali). The age of the patients enrolled in this study was from 6 months old. The plasma samples were kept at – 80°C until lumefantrine analysis using high performance liquid chromatography was performed.ResultsWe included 1076 subjects, of which 595 were females and a mean age of 12 years old in this analysis.The median concentration was 66% higher (p |
doi_str_mv | 10.1136/bmjgh-2016-000260.61 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2551753633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2551753633</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1591-bb7b49c2a8502aea711f47d5ad2a77a089d05c7f8cf1faab28f423367b475e173</originalsourceid><addsrcrecordid>eNqNkD9PwzAQxS0EElXpN2CwxJzWdmI7Ga3WoZbyT6kLo-WkCVBRWpJ2gE-PSxhgY7k73b3fO-kBcIvRFGOfzard9unZIwgzDyFEGJoyfAFGBNHI4xEKL3_N12DS91snw9wVxEbgM1mnMhaZLlUm4UKtinyltMozKGItS1jKQmq3eJBQl1LoVGYa5jFcZ_M8LRI1F1ouYCoSUSoBC6GVE6zgo9JLKEotU6mXsvT-fFHZGVA34Kq1r30z-eljsI6lni-9JL93volXYRphr6p4FUQ1sSFFxDaWY9wGfEPthljOLQqjDaI1b8O6xa21FQnbgPg-cxSnDeb-GNwNvodu_35q-qPZ7k_dm3tpCKWYU5_5vlMFg6ru9n3fNa05dC87230YjMw5aPMdtDkHbYagDcMOmw2Yu_6P-ALNTHZ8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2551753633</pqid></control><display><type>article</type><title>LUMEFANTRINE DISPOSITION AFTER REPETITIVE TREATMENT OF UNCOMPLICATED MALARIA PATIENTS WITH ARTEMETHER-LUMEFANTRINE IN MALI</title><source>BMJ Journals (Open Access)</source><source>PubMed Central</source><creator>Tekete, Mamadou ; Burhenne, Juergen ; Fofana, Bakary ; Toure, Sekou ; Dama, Souleymane ; Dara, Nianwalou ; Traore, Oumar ; Sidibe, Bouran ; Djimde, Abdoulaye ; Haefeli, Walter ; Borrmann, Steffen</creator><creatorcontrib>Tekete, Mamadou ; Burhenne, Juergen ; Fofana, Bakary ; Toure, Sekou ; Dama, Souleymane ; Dara, Nianwalou ; Traore, Oumar ; Sidibe, Bouran ; Djimde, Abdoulaye ; Haefeli, Walter ; Borrmann, Steffen</creatorcontrib><description>BackgroundSince 2006 the national malaria control program in Mali recommended artemether-lumefantrine (AL) as the first-line treatment of uncomplicated malaria. The role of lumefantrine in this combination is to eliminate remaining parasites after the action of artemether and to protect the patient against a new blood infection. Some studies showed a correlation between lumefantrine's day 7 concentration and the efficacy of AL after treatment of a single episode of malaria. The objective of this work is to validate this observation after repetitive treatment of uncomplicated malaria patients with AL.MethodsDuring a phase IIIb/IV comparative, randomised, multicentre, clinical study of artemisinin-based combination therapies, we collected plasma on Day 7 from patients treated with standard dose of AL in Sotuba, Bougoula Hameau, and Kolle (Mali). The age of the patients enrolled in this study was from 6 months old. The plasma samples were kept at – 80°C until lumefantrine analysis using high performance liquid chromatography was performed.ResultsWe included 1076 subjects, of which 595 were females and a mean age of 12 years old in this analysis.The median concentration was 66% higher (p<0.0001) in patients without recurrent parasite on day 28 compared to patients with recurrent parasitaemia: 509.1 ng/ml (inter quartile range: 329.6–723.2; n=919) vs 372.5 (255.7–538.4; n=157). Day 7 concentrations increased with age; the difference between age group was statistically significant: 305.9 (207.3–491.5, n=140), 447 (290.7–622.9, n=399), 544.7 (383.9–738.5, n=254) and 571.1 (378.8–850.9), n=283) in patients under 5 years old, 5–9 years old, 10–14 years old and 15 years old and older, respectively. Girls under 5 years old had a lower lumefantrine concentration at day 7 compared to other age groups of 223.3 ng/ml (159.7–425.6, n=37).ConclusionsWe found a lower concentration of lumefantrine in patients with recurrent parasitaemia at day 28.</description><identifier>ISSN: 2059-7908</identifier><identifier>EISSN: 2059-7908</identifier><identifier>DOI: 10.1136/bmjgh-2016-000260.61</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Age ; Global health ; Malaria</subject><ispartof>BMJ global health, 2017-02, Vol.2 (Suppl 2), p.A24-A24</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2017 This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://gh.bmj.com/content/2/Suppl_2/A24.2.full.pdf$$EPDF$$P50$$Gbmj$$Hfree_for_read</linktopdf><linktohtml>$$Uhttp://gh.bmj.com/content/2/Suppl_2/A24.2.full$$EHTML$$P50$$Gbmj$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,27549,27550,27924,27925,77601,77632</link.rule.ids></links><search><creatorcontrib>Tekete, Mamadou</creatorcontrib><creatorcontrib>Burhenne, Juergen</creatorcontrib><creatorcontrib>Fofana, Bakary</creatorcontrib><creatorcontrib>Toure, Sekou</creatorcontrib><creatorcontrib>Dama, Souleymane</creatorcontrib><creatorcontrib>Dara, Nianwalou</creatorcontrib><creatorcontrib>Traore, Oumar</creatorcontrib><creatorcontrib>Sidibe, Bouran</creatorcontrib><creatorcontrib>Djimde, Abdoulaye</creatorcontrib><creatorcontrib>Haefeli, Walter</creatorcontrib><creatorcontrib>Borrmann, Steffen</creatorcontrib><title>LUMEFANTRINE DISPOSITION AFTER REPETITIVE TREATMENT OF UNCOMPLICATED MALARIA PATIENTS WITH ARTEMETHER-LUMEFANTRINE IN MALI</title><title>BMJ global health</title><description>BackgroundSince 2006 the national malaria control program in Mali recommended artemether-lumefantrine (AL) as the first-line treatment of uncomplicated malaria. The role of lumefantrine in this combination is to eliminate remaining parasites after the action of artemether and to protect the patient against a new blood infection. Some studies showed a correlation between lumefantrine's day 7 concentration and the efficacy of AL after treatment of a single episode of malaria. The objective of this work is to validate this observation after repetitive treatment of uncomplicated malaria patients with AL.MethodsDuring a phase IIIb/IV comparative, randomised, multicentre, clinical study of artemisinin-based combination therapies, we collected plasma on Day 7 from patients treated with standard dose of AL in Sotuba, Bougoula Hameau, and Kolle (Mali). The age of the patients enrolled in this study was from 6 months old. The plasma samples were kept at – 80°C until lumefantrine analysis using high performance liquid chromatography was performed.ResultsWe included 1076 subjects, of which 595 were females and a mean age of 12 years old in this analysis.The median concentration was 66% higher (p<0.0001) in patients without recurrent parasite on day 28 compared to patients with recurrent parasitaemia: 509.1 ng/ml (inter quartile range: 329.6–723.2; n=919) vs 372.5 (255.7–538.4; n=157). Day 7 concentrations increased with age; the difference between age group was statistically significant: 305.9 (207.3–491.5, n=140), 447 (290.7–622.9, n=399), 544.7 (383.9–738.5, n=254) and 571.1 (378.8–850.9), n=283) in patients under 5 years old, 5–9 years old, 10–14 years old and 15 years old and older, respectively. Girls under 5 years old had a lower lumefantrine concentration at day 7 compared to other age groups of 223.3 ng/ml (159.7–425.6, n=37).ConclusionsWe found a lower concentration of lumefantrine in patients with recurrent parasitaemia at day 28.</description><subject>Age</subject><subject>Global health</subject><subject>Malaria</subject><issn>2059-7908</issn><issn>2059-7908</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><recordid>eNqNkD9PwzAQxS0EElXpN2CwxJzWdmI7Ga3WoZbyT6kLo-WkCVBRWpJ2gE-PSxhgY7k73b3fO-kBcIvRFGOfzard9unZIwgzDyFEGJoyfAFGBNHI4xEKL3_N12DS91snw9wVxEbgM1mnMhaZLlUm4UKtinyltMozKGItS1jKQmq3eJBQl1LoVGYa5jFcZ_M8LRI1F1ouYCoSUSoBC6GVE6zgo9JLKEotU6mXsvT-fFHZGVA34Kq1r30z-eljsI6lni-9JL93volXYRphr6p4FUQ1sSFFxDaWY9wGfEPthljOLQqjDaI1b8O6xa21FQnbgPg-cxSnDeb-GNwNvodu_35q-qPZ7k_dm3tpCKWYU5_5vlMFg6ru9n3fNa05dC87230YjMw5aPMdtDkHbYagDcMOmw2Yu_6P-ALNTHZ8</recordid><startdate>201702</startdate><enddate>201702</enddate><creator>Tekete, Mamadou</creator><creator>Burhenne, Juergen</creator><creator>Fofana, Bakary</creator><creator>Toure, Sekou</creator><creator>Dama, Souleymane</creator><creator>Dara, Nianwalou</creator><creator>Traore, Oumar</creator><creator>Sidibe, Bouran</creator><creator>Djimde, Abdoulaye</creator><creator>Haefeli, Walter</creator><creator>Borrmann, Steffen</creator><general>BMJ Publishing Group LTD</general><scope>9YT</scope><scope>ACMMV</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201702</creationdate><title>LUMEFANTRINE DISPOSITION AFTER REPETITIVE TREATMENT OF UNCOMPLICATED MALARIA PATIENTS WITH ARTEMETHER-LUMEFANTRINE IN MALI</title><author>Tekete, Mamadou ; Burhenne, Juergen ; Fofana, Bakary ; Toure, Sekou ; Dama, Souleymane ; Dara, Nianwalou ; Traore, Oumar ; Sidibe, Bouran ; Djimde, Abdoulaye ; Haefeli, Walter ; Borrmann, Steffen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1591-bb7b49c2a8502aea711f47d5ad2a77a089d05c7f8cf1faab28f423367b475e173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Age</topic><topic>Global health</topic><topic>Malaria</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tekete, Mamadou</creatorcontrib><creatorcontrib>Burhenne, Juergen</creatorcontrib><creatorcontrib>Fofana, Bakary</creatorcontrib><creatorcontrib>Toure, Sekou</creatorcontrib><creatorcontrib>Dama, Souleymane</creatorcontrib><creatorcontrib>Dara, Nianwalou</creatorcontrib><creatorcontrib>Traore, Oumar</creatorcontrib><creatorcontrib>Sidibe, Bouran</creatorcontrib><creatorcontrib>Djimde, Abdoulaye</creatorcontrib><creatorcontrib>Haefeli, Walter</creatorcontrib><creatorcontrib>Borrmann, Steffen</creatorcontrib><collection>BMJ Journals (Open Access)</collection><collection>BMJ Journals:Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>BMJ global health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tekete, Mamadou</au><au>Burhenne, Juergen</au><au>Fofana, Bakary</au><au>Toure, Sekou</au><au>Dama, Souleymane</au><au>Dara, Nianwalou</au><au>Traore, Oumar</au><au>Sidibe, Bouran</au><au>Djimde, Abdoulaye</au><au>Haefeli, Walter</au><au>Borrmann, Steffen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LUMEFANTRINE DISPOSITION AFTER REPETITIVE TREATMENT OF UNCOMPLICATED MALARIA PATIENTS WITH ARTEMETHER-LUMEFANTRINE IN MALI</atitle><jtitle>BMJ global health</jtitle><date>2017-02</date><risdate>2017</risdate><volume>2</volume><issue>Suppl 2</issue><spage>A24</spage><epage>A24</epage><pages>A24-A24</pages><issn>2059-7908</issn><eissn>2059-7908</eissn><abstract>BackgroundSince 2006 the national malaria control program in Mali recommended artemether-lumefantrine (AL) as the first-line treatment of uncomplicated malaria. The role of lumefantrine in this combination is to eliminate remaining parasites after the action of artemether and to protect the patient against a new blood infection. Some studies showed a correlation between lumefantrine's day 7 concentration and the efficacy of AL after treatment of a single episode of malaria. The objective of this work is to validate this observation after repetitive treatment of uncomplicated malaria patients with AL.MethodsDuring a phase IIIb/IV comparative, randomised, multicentre, clinical study of artemisinin-based combination therapies, we collected plasma on Day 7 from patients treated with standard dose of AL in Sotuba, Bougoula Hameau, and Kolle (Mali). The age of the patients enrolled in this study was from 6 months old. The plasma samples were kept at – 80°C until lumefantrine analysis using high performance liquid chromatography was performed.ResultsWe included 1076 subjects, of which 595 were females and a mean age of 12 years old in this analysis.The median concentration was 66% higher (p<0.0001) in patients without recurrent parasite on day 28 compared to patients with recurrent parasitaemia: 509.1 ng/ml (inter quartile range: 329.6–723.2; n=919) vs 372.5 (255.7–538.4; n=157). Day 7 concentrations increased with age; the difference between age group was statistically significant: 305.9 (207.3–491.5, n=140), 447 (290.7–622.9, n=399), 544.7 (383.9–738.5, n=254) and 571.1 (378.8–850.9), n=283) in patients under 5 years old, 5–9 years old, 10–14 years old and 15 years old and older, respectively. Girls under 5 years old had a lower lumefantrine concentration at day 7 compared to other age groups of 223.3 ng/ml (159.7–425.6, n=37).ConclusionsWe found a lower concentration of lumefantrine in patients with recurrent parasitaemia at day 28.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/bmjgh-2016-000260.61</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2059-7908 |
ispartof | BMJ global health, 2017-02, Vol.2 (Suppl 2), p.A24-A24 |
issn | 2059-7908 2059-7908 |
language | eng |
recordid | cdi_proquest_journals_2551753633 |
source | BMJ Journals (Open Access); PubMed Central |
subjects | Age Global health Malaria |
title | LUMEFANTRINE DISPOSITION AFTER REPETITIVE TREATMENT OF UNCOMPLICATED MALARIA PATIENTS WITH ARTEMETHER-LUMEFANTRINE IN MALI |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T01%3A44%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LUMEFANTRINE%20DISPOSITION%20AFTER%20REPETITIVE%20TREATMENT%20OF%20UNCOMPLICATED%20MALARIA%20PATIENTS%20WITH%20ARTEMETHER-LUMEFANTRINE%20IN%20MALI&rft.jtitle=BMJ%20global%20health&rft.au=Tekete,%20Mamadou&rft.date=2017-02&rft.volume=2&rft.issue=Suppl%202&rft.spage=A24&rft.epage=A24&rft.pages=A24-A24&rft.issn=2059-7908&rft.eissn=2059-7908&rft_id=info:doi/10.1136/bmjgh-2016-000260.61&rft_dat=%3Cproquest_cross%3E2551753633%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b1591-bb7b49c2a8502aea711f47d5ad2a77a089d05c7f8cf1faab28f423367b475e173%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2551753633&rft_id=info:pmid/&rfr_iscdi=true |